Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opportunities Ripe For Device Firms In Emerging-Market Heartlands

This article was originally published in PharmAsia News

Executive Summary

Device and diagnostics companies can find new growth opportunities by marketing their wares in developing countries' smaller cities and towns, not just big ones, experts said Sept. 30 at a Wells Fargo Securities Emerging Markets Forum in New York

You may also be interested in...



J&J, Medtronic Adapt To Changing Chinese Medical Device Market - Ernst &Young Report

As the Chinese government increases healthcare spending and the country's middle class rises to dominate the consumer market, global medical device makers are taking note. Johnson & Johnson and Medtronic are switching strategies to develop and market products that are tailored to the growing middle class

J&J, Medtronic Adapt To Changing Chinese Medical Device Market - Ernst &Young Report

As the Chinese government increases healthcare spending and the country's middle class rises to dominate the consumer market, global medical device makers are taking note. Johnson & Johnson and Medtronic are switching strategies to develop and market products that are tailored to the growing middle class

Navigating Chinese Health Care Reform: Opportunities And Pitfalls

Health care reform in China will infuse a significant amount of money into Chinese health services, some of which will trickle down to support new technologies, but medical device manufacturers should proceed with caution, experts advise

Latest News
See All
UsernamePublicRestriction

Register

SC073285

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel